Company news

CytoSorbents Corporation news in 2021

CytoSorbents Corporation's news releases, calls and decks from 2021, newest first.

View company

CytoSorbents Appoints Daniel Wendt, MD, PhD, MHBA, FECTS as Vice President, Medical Affairs Cardiovascular

December 20, 2021

CytoSorbents Announces Publication of U.S. CTC Multicenter Registry Results Using CytoSorb® in Critically Ill COVID-19 Patients on Extracorporeal Membrane Oxygenation (ECMO)

December 19, 2021

CytoSorbents Reports Full Third Quarter 2021 Financial and Operational Results

November 3, 2021

First Patient Enrolled in U.S. STAR-T Pivotal Trial Evaluating the DrugSorb-ATR™ Antithrombotic Removal System to Remove Ticagrelor During Cardiothoracic Surgery

October 13, 2021

CytoSorbents Receives Full FDA Investigational Device Exemption (IDE) Approval to Begin U.S. STAR-D Trial on Apixaban and Rivaroxaban Removal by the DrugSorb-ATR™ Antithrombotic Removal System During Urgent Cardiothoracic Surgery

October 11, 2021

CytoSorbents Provides Preliminary Third Quarter Business Update and Revised 2021 Product Revenue Guidance

October 11, 2021

CytoSorbents Announces Availability of Preliminary Data Abstracts from Two Endocarditis Studies, including the REMOVE study, to be Presented at the EACTS Conference

October 6, 2021

CytoSorbents Announces Filing of an Investigational Device Exemption (IDE) for the U.S. Clinical Trial on Apixaban and Rivaroxaban Removal by the DrugSorb-ATR™ Antithrombotic Removal System During Urgent Cardiothoracic Surgery

September 9, 2021

CytoSorbents Announces Webinar Discussing Topline Results from the U.S. CTC Registry using CytoSorb® in Critically Ill COVID-19 Patients on Extracorporeal Membrane Oxygenation (ECMO)

September 7, 2021

Topline Results from CytoSorbents' U.S. CTC Multicenter Registry Demonstrate High Survival using CytoSorb® in Critically Ill COVID-19 Patients on Extracorporeal Membrane Oxygenation (ECMO)

August 31, 2021

CytoSorbents and Aferetica Announce the Commercial Launch in Italy of the PerSorb™ Adsorber and PerLife™ Organ Perfusion System, respectively, at the European Society of Organ Transplantation Congress

August 29, 2021

Second U.S. FDA Breakthrough Device Designation Granted to CytoSorbents' DrugSorb-ATR™ Antithrombotic Removal System Adding the Removal of Market-Leading Direct Oral Anticoagulants During Urgent Cardiothoracic Surgery

August 11, 2021

CytoSorbents Reports Second Quarter 2021 Financial and Operational Results

August 2, 2021

CytoSorbents Completes its Mission 100,000 International Fundraising Campaign to Fight the Spread of COVID-19 for Global Humanitarian Organization, CARE

July 29, 2021

CytoSorbents Receives Full FDA Approval of Investigational Device Exemption (IDE) for U.S. STAR-T Trial on Ticagrelor Removal During Cardiothoracic Surgery

July 5, 2021

CytoSorbents Appoints Terri Anne Powers, IRC as Vice President of Investor Relations and Corporate Communications

May 31, 2021

CytoSorb® Registered and Commercially Available in Singapore

May 24, 2021

CytoSorbents Awarded $1.5 Million Sequential Phase II SBIR Contract to Advance the Treatment of Severe Hyperkalemia in Traumatic Injury

May 10, 2021

CytoSorbents Reports First Quarter 2021 Financial and Operational Results

May 3, 2021

CytoSorbents to Report Q1 2021 Operating and Financial Results

April 26, 2021

U.S. FDA Approves CytoSorbents to Initiate U.S. STAR-T Trial For Ticagrelor Removal During Cardiothoracic Surgery

April 18, 2021

CytoSorbents Announces Lease of New Global Headquarters in Princeton, New Jersey

March 28, 2021

CytoSorbents Announces Filing of an Investigational Device Exemption (IDE) for U.S. Trial on Ticagrelor Removal During Cardiothoracic Surgery

March 15, 2021

CytoSorbents Announces 2020 Financial and Operational Results

March 8, 2021

CytoSorbents to Report Fiscal 2020 Operating and Financial Results

February 28, 2021

CytoSorbents Appoints David D. Cox, PhD, MBA as Vice President - Global Regulatory Affairs

January 20, 2021

CytoSorbents Announces Approval of CytoSorb® in Korea in Collaboration with Partner Fresenius Medical Care

January 18, 2021

CytoSorbents Reports Preliminary Fourth Quarter and Full Year 2020 Revenue

January 11, 2021

CytoSorbents Appoints James Komsa as Vice President - U.S. Sales and Marketing

January 10, 2021

Health Canada Authorizes CytoSorb for Use in Hospitalized COVID-19 Patients

January 3, 2021

Calls in 2021

Decks in 2021